Combining Modern Pharmacology with Integrative Medicine: A Biopsychosocial Model for Comprehensive Pain Care

*Agnes Mazic De Sonis*

#### **Abstract**

The medical community recognized last decennia the multidimensional nature of pain and proposed multimodal biopsychosocial management. The most compelling reason to embrace integrative pain strategies is to mitigate patient risk. For patients with chronic pain and pain refractory to conservative medicine, it is essential to assess all factors involved with the chronicity. With significant themes, nutrition and microbiome, neuroplasticity, homeostasis, and the side effects of medication, acupuncture has progressively gained a place in this multimodal evaluation. Therapeutic multimodality approaches the perspective of physiological rehabilitation and chronobiological improvement of the quality of life. Illustrated by various clinical situations, the objective of management is to seek a synergy in the mechanisms of action of treatments to improve quality of life and reduce the need for xenobiotics and, consequently, the side effects. The mechanism of action of integrative medicine, and acupuncture improved with a better understanding of genetics, and epigenetics. As opposed to sham and placebo, acupuncture activates other brain regions. In controlled trials, the strict inclusion and exclusion criteria result in the treatment of a "selected" patient population, which is not always comparable to the patients seen in daily practice. The integrative approach is better illustrated by case reports.

**Keywords:** acupuncture, nutrition, microbiome, p4medicine, personalized medicine, integrative

#### **1. Introduction**

Even for modern medicine, chronic pain remains a complex, multi-faceted problem of nociception, inflammation, and abnormal physiology in the nervous system. Thanks to the knowledge of epigenetics, it becomes clear that environmental factors such as nutrition and chronobiology can modify the parameters involved in all sensitization mechanisms in chronic pain diseases. The deranged sensitization mechanisms suggest restoring the hypersensitive structures to their normal status besides the analgesic treatment.

While more research is needed to understand the progression from acute to chronic pain, the limited pain management strategies have not addressed the scope of pain.

Increased costs and lack of evidence of efficacy are not, according to the physicians (ACP) Clinical Practice Guideline, evidence-informed, comprehensive pain care while conceding that past strategies generally, and the use of opioid medications specifically, have not remedied but rather exacerbated chronic pain, abuse, addiction, illness behavior, and disability [1].

Awareness of serious adverse effects of medications is growing, including the escalating rates of accidental overdoses of prescription opioids and the development of opioid tolerance and hyperalgesia [2].

IASP 2023 global defines integrative pain care as temporally coordinated, mechanism-guided, individualized, and evidence-based integration of multiple pain treatment interventions. Considering the ever-growing burden of chronic pain, current pain management models frequently do not address the clinical problem. The complexity of chronic pain justifies a bio-psycho-social framework, integrating different management and treatment approaches is preferred.

#### **2. Pain chronobiology and epigenetic regulation**

A total of 30% genetic and 70% epigenetic factors, such as nutrition and intestinal flora, social, psychological, and affective define the status of an individual [3]. The sensibility for pain is affected by 20 genes. These are also responsible for the variation in reaction to pharmacologic treatment (see **Figure 1**) [5].

The ignition or blocking of specific genes is epigenetically regulated. It is also sensitive to environmental factors [5].

Intra and extracellular homeostasis regulates the peripheral sensitization of the primary nociceptors. Inflammation activates the bidirectional signaling that it modulates. Even though there is no immunological response, certain bacterial infections could be accompanied by a hyperalgesic state (see **Figure 2**) [6].

Pharmacological treatment of chronic pain has dose-dependent side effects, including opioid tolerance, addiction, and even death. Chronic pain involves neuroplastic changes, and neuroinflammation becomes a key question in central sensitization (**Figure 3**).

Pain induces arousal and triggers other neurobiological stress sequels, thus disturbing sleep and enhancing pain sensitivity. Disturbed sleep or pain may induce a cycle whereby both components stabilize or augment each other. Therefore, management of sleep disturbance may alleviate pain, whereas pain relief may restore sleep and enhance long-term pain relief.

Treatment should target the different mechanisms of pain and may require a combination of treatment options. Combining therapies, such as acupuncture, with traditional pharmacology is still in its infancy.

Acupuncture influences the opioid and cannabinoid system by releasing endogenous receptor ligands. Low-dose naltrexone also acts on both systems and upregulates the opioid and cannabinoid receptors.

Dietary choices and drug use (proton pump inhibitors, NSAIDs, steroids, antibiotics, and hormones) can influence inflammation by altering the microbiome and gut permeability. The balance of microorganisms can affect the absorption of nutrients, drugs, and the function of the immune system leading to low-grade inflammation.

*Combining Modern Pharmacology with Integrative Medicine: A Biopsychosocial Model… DOI: http://dx.doi.org/10.5772/intechopen.112906*

**Figure 1.**

*Influences of the epigenetic modulation system. From Ref. [4].*

**Figure 2.** *Interactions leading to vulnerability for pain.*

**Figure 3.** *Schema of gut-brain interaction from [7].*

One day after morphine treatment, there is a significant shift in the gut microbiome and metabolome. Morphine-induced gut microbial dysbiosis exhibited distinct characteristic signatures. Drug-microbiota dynamics could help to identify drug-drug interactions and explain inter-individual variation in drug efficacy and adverse effects. The gut microbiome can affect all classes of drugs.

The gastrointestinal microbiome plays a significant role in responses to opioids, including the development of tolerance.

The neuro-immune interactions induced by morphine have direct intestinal functional consequences. Morphine disrupts gut barrier function in a toll-like receptor (TLR)-dependent manner [8]. Low-dose naltrexone (LDN) acts on various gut mechanisms.

Analgesic tolerance to opioids induced by the gut-brain interaction suggests that peripheral mechanisms from the gut can profoundly affect the central control of opioid function. The answer to treatment can be modulated by genetic variations and the inter-individual differences in the bacterial flora of the human digestive tract. The pharmacokinetics of drug metabolism was redefined by the progress in

*Combining Modern Pharmacology with Integrative Medicine: A Biopsychosocial Model… DOI: http://dx.doi.org/10.5772/intechopen.112906*

understanding the host-microbial interaction and has improved the management of drug (ab)users.

Acupuncture influences different molecules and receptors, such as GABA, glutamate, and its other receptors (AMPA, NMDA), serotonin (5HT), and the opioid system. The treatment objective is addressing pain and preventing chronicity, focusing on drug and non-drug strategies. Therapeutics directed at maintaining microbiome homeostasis during opioid use may reduce the associated comorbidities.

#### **2.1 Integrative pain medicine and mitigation of risk**

The overlap with conventional care is growing as the scientific basis for these therapies expands. Integration across the lifespan to include personal, predictive, preventive, and participatory care.

Personalization of treatment usually means targeting a smaller subset of patients who share a particular phenotype. The economic or financial viability of stratified medicine versus empiric medicine (a medicine prescribed to all patients with a specific condition) was evaluated by Trusheim and Berndt [9] and Ozdemir et al. [10].

Personalized medicine goals require knowledge of which treatment is best for each individual, and promises increased efficiencies for health care systems. Much emphasis in developing customized therapies has been on genetic polymorphisms and blood biomarkers [10]. The predictive capacity of the data pattern must be defined. Determining clinical variables by interview remains the most helpful tool available to a treating physician for selecting the best treatment options on a case-by-case basis. Several recent studies note the need for new models and frameworks that can consistently provide professionals and consumers with helpful knowledge that physicians can meaningfully apply [11].

#### *2.1.1 Acupuncture*

Under the premise of selecting acupoints along the meridians and adopting reinforcement and reduction manipulations, acupuncture will bidirectionally regulate the clinical symptoms and signs.

The same stimulation parameters applied to the same acupoint or nerve may result in opposite regulation (restoring homeostatic balance or normalizing function), the so-called "bidirectional regulation".

The peripheral lesions around the needle trigger physiological reactions and initiate a cascade of survival reactions. Via the reflex of the axon due to the increased blood flow in the muscle, Calcitonin Gene-Related Peptide (CGRP) and nitrous oxide (NO) are released after manual acupuncture and contribute to tissue healing [12, 13].

Acupuncture induces a brain response to the stimulation of sensory nerves, making it a physiological therapy. Acupuncture normalizes physiological homeostasis and promotes self-healing. The primary nociceptors are complex in the ligand expression of neurotransmitters and receptors, enabling autocrine and paracrine interactions.

Primary nociceptors generate bidirectional efferent messages toward the innervated tissues, and can modify (facilitate or inhibit) sensory information even before transmission to the central nervous system.

Nociceptors seem to have a mind of their own (see **Figures 4** and **5**) [13].

Pain control might be influenced by the modulation of different molecules and receptors such as GABA, glutamate, and its other receptors (AMPA, NMDA, etc.),

**Figure 4.** *Hyperalgesia at a cellular level.*

the serotonin (5HT) system, the opioid system, norepinephrine (NE), cholinergic receptors, etc. Low-frequency electroacupuncture (EA) has a better effect than a high frequency (100 Hz).

Bidirectional regulation is a unique phenomenon of acupuncture therapy, seen in multiple systemic, cellular, and molecular functional systems. Not all acupoints unconditionally produce the bidirectional regulatory effect, and the corresponding factors remain to be investigated. The body's homeostatic regulation can achieve bidirectional regulation by acupuncture or peripheral stimulation in different functional states. It is not a simple physiological response but a complex pathophysiological process [15, 16].

Acupuncture stimulates brain responses in cortical and subcortical regions, associated with modulation of the pain sensation and perception, including activation in the sensorimotor cortical and deactivation in the limbic-para limbic-neocortical network as demonstrated with functional neuroimaging studies [17]. It is postulated that the therapeutic response to acupuncture, such as down-regulation of inflammation and autonomic nervous system-mediated pain relief, is provided by a mechanistic pathway of the autonomic nervous system.

Event-related (er)-fMRI is used to evaluate the brain correlates of acupuncture stimulation, it seems to be associated with different autonomic nervous system outflow responses to needle stimuli and may result from other sensations elicited by stimuli at different bodily locations [18]*.* In vivo μ-opioid receptor (MOR) binding effects of traditional Chinese acupuncture versus sham acupuncture were found in chronic pain patients diagnosed with fibromyalgia [17]*.*

*Combining Modern Pharmacology with Integrative Medicine: A Biopsychosocial Model… DOI: http://dx.doi.org/10.5772/intechopen.112906*

#### **Figure 5.**

*Interactions at the nerve endings [14].*

#### *2.1.2 Nutrition and microbiome*

In addition to the severity of the underlying condition, interindividual variability in chronic pain depends on many factors, including its sociocultural context, patients' genetic backgrounds, psychological factors, and pathophysiology, that can be modulated and monitored by altering nutritional habits [19]. Specific nutritional deficiencies can be associated with pain states. A study discovered that patients with pain with insufficient vitamin D levels needed twice the dose of opioids for twice as long as patients without a deficiency.

Many different types of elimination diets can be useful for patients to try.

Food and nutrition are foundational tools in treating painful and inflammatory conditions. Compelling evidence shows the benefits of a healthy diet composed mainly of unprocessed, plant-based foods.

Sugars and facts may feed into many anabolic and catabolic pathways, the handling of the body of nutrients depends on strategically positioned metabolic sensors that link the intrinsic nutritional value of a meal with intermediary metabolism.

Assessing the nutritional status is a cornerstone of integrative pain medicine. Dietary choices increase or decrease inflammation. Free-radical damage of tissues, induced by inflammation, impedes healing mechanisms, and reduces pH to levels where normal enzymatic reactions are no longer optimized. Inflammation can be reduced by an anti-inflammatory diet, such as the Mediterranean diet—which is high in vegetables, fruits, whole grains, fish, and healthy oils but low in meat (**Figure 6**) [21].

**Figure 6.** *Schema of microbiota regulation [20].*

#### *2.1.3 The effects of drug therapy on the gut microbiome*

The individual diversity of the gut microbiome promotes inter-individual variations with pharmacotherapy, drug-induced toxicity, and efficacy.

The gut microbiome is affected by drug effects and the GI tract environment can be altered (e.g., pH and transit time), mucosa integrity, host and bacterial metabolic aqctivity, and the production of microbial metabolites. These changes can have secondary effects on the microbiome and cause drug-drug interactions. Drugs may also challenge both the integrity and permeability of the intestinal mucosa.

#### *2.1.3.1 Drugs and polypharmacy*

The combined use of non-steroidal anti-inflammatory drugs (NSAIDs) and PPIs differentially influenced the relative abundance of Bacteroides spp. and Erysipelotrichaceae spp. Compared to NSAIDs alone, the co-administration of drugs may precipitate shifts in the composition of the microbiota to favor the abundance of microbial taxa that have a metabolizing capacity for those drugs [22].

#### *2.1.3.2 Effect of diet-induced changes on the gut microbiome and drug pharmacokinetics*

Drug pharmacokinetics may be modulated by probiotics by changing the composition or metabolic activity of the gut microbiota. Probiotic treatment was shown to increase the microbiota-mediated degradation of the antipyretic and

*Combining Modern Pharmacology with Integrative Medicine: A Biopsychosocial Model… DOI: http://dx.doi.org/10.5772/intechopen.112906*

analgesic paracetamol, which may be mediated by probiotic-induced modulation of gut microbial enzyme activity.

Some patients are more at risk for food-drug interaction, such as chronic disease, elderly, malnourished, infant, and pregnant women.

Meanwhile, examining and explaining how gut microbiota regulates drug metabolism and toxicity will assist personalized medicine and facilitate strategies for creating new drugs with desired functionality.

#### **2.2 Towards circuit-based tVNS: translational approaches**

It is important to estimate the independent effects of the disease or drug treatment in animal and human studies, as both the CNS-related disease itself and the pharmacological treatment of the disease can alter the composition of the microbiota.

This microbiome impacts the properties and function of microglia involved in pain sensitization. To maintain homeostasis, the vagal nerve (VN) actively participates in bidirectional interactions between the gut microbiome and the brain. VN electroacupuncture promotes the expression and localization of junction proteins, decreasing intestinal permeability and protecting the intestinal epithelial barrier. Complex reflexes, such as the autonomic reflex, can be used to explain some therapeutic effects of acupuncture.

Administration of pre/probiotics to modify vagal nerve function could be a promising strategy for treating central nervous system disorders (**Figure 7**).

In human studies, the vital role of the VN in modulating food intake, energy metabolism, and glycemic control has been demonstrated more recently [23–27]. Across disciplines the pathophysiology of several disorders is attributed to the VN on a behavioral and psychological level; VN stimulation, remarkably non-invasive VN stimulation, has been studied, allowing a better understanding of the mechanisms by which VN stimulation exerts psychological and physiological effects. A more important pathway for acupuncture stimuli is via the autonomic center in the brain that works to up or down-regulate the sympathetic or para-sympathetic output. Neuroendocrine and neuroimmune pathways are also crucial for maintaining the stability of various functional systems in the body, and they can be affected by acupuncture stimulation.

#### *2.2.1 Nutraceuticals and others*

The purified products derived from plants, animals, microorganisms (e.g., essential fatty acids and enzymes), and marine sources (e.g., glucosamine, chitosan, fish oils) are called nutraceuticals. They are sold in medicinal forms e.g., tablets, capsules, and powders. The bioactive agents the nutraceuticals deliver may also be obtained through a healthy diet. They provide, however, the advantages of a formulation that promotes the absorption and the physiological effect [19].

#### *2.2.1.1 Curcumin*

Hu et al. [28] recently determined that curcumin attenuates opioid-induced hyperalgesia by inhibiting Ca2+/calmodulin-dependent protein kinase II α activity and found that a nano-formulation of poly(lactic-co-glycolide)-curcumin-curcumin may reverse opioid-induced hyperalgesia by inhibiting caMKIIa and downstream signaling.

**Figure 7.**

*The multiple bidirectional communication routes between the brain and the gut microbiota. These routes include the vagal nerve, the hypothalamic-pituitary-adrenal axis (HPA), cytokines produced by the immune system, tryptophan metabolism, and short-chain fatty acid production. Adopted from [16].*

Curcumin induces mitochondrial biogenesis, and has a direct activity on reactive oxygen species, and induction of NRF2. It regulates the epigenetic patterns and has a synergistic activity on drugs used to treat different painful conditions. The low bioavailability of curcumin can be improved by bio-optimization techniques, thus increasing the therapeutic and preventive potentials of the natural substance [29, 30].

*Combining Modern Pharmacology with Integrative Medicine: A Biopsychosocial Model… DOI: http://dx.doi.org/10.5772/intechopen.112906*

**Figure 8.**

*Activation of microglia by toll-like receptor (TLR) agonists and by palmitoylethanolamide (PEA). Adopted from [31].*

#### *2.2.1.2 PEA palmitoylethanolamide*

Glia may produce their own endogenous "painkillers" and anti-inflammatory agents through their own modulators. These modulators decrease the winding-up mechanisms in neuropathic pain. Anandamide and its sister molecule PEA are such modulators, and induce a "winding down" in chronic and neuropathic pain and neuroinflammation. Both molecules are classical autacoids, fulfilling the three criteria required for autacoids of lipid transmitters.

PEA is a modulator that reduces pain by decreasing winding-up mechanisms in neuropathic pain and neuroinflammation (**Figure 8**).

#### *2.2.1.3 Low-dose naltrexone*

Within a specific dosage window, opioid antagonists such as naltrexone can exert a "paradoxical" analgesic effect. Low-dose naltrexone (LDN) produces the modulation of neuro-inflammation, and stimulates the glial cells to release inflammatory chemicals in the central nervous system. The dosage producing these effects is low compared to the dosage approved for all alcohol and opioid dependency. The pharmacological actions enhance the analgesic effects of endogenous opioids and cannabinoids. Naltrexone modulates the toll-like receptor 4, NO, and filamin A. LDN is safe, with very few side effects, and recent clinical pilot trials in fibromyalgia and multiple sclerosis showed pain reduction and quality of life enhancing impact [32]. It also improved pain tolerance in cold pressor tests and the ability of post-detoxification patients to relate interpersonally with other participants in human relationships (**Tables 1** and **2**).


**Table 1.**

*Summary of clinical experience with low-dose naloxone/naltrexone. Adopted from [33].*

#### **3. Observational studies to evaluate the effectiveness of healthcare**

The fundamentals of neurophysiology learn that the revalidation of the main chronobiological rhythm results in regulating sleep, food, and the vicious circle involved in pain sensitization.

Although randomized controlled trials are considered the most valuable method for proving the efficacy of a treatment. This method cannot be applied to every treatment. Black [46] discusses the advantages and disadvantages of strictly *Combining Modern Pharmacology with Integrative Medicine: A Biopsychosocial Model… DOI: http://dx.doi.org/10.5772/intechopen.112906*


#### **Table 2.**

*Clinical experience on LDN in multiple sclerosis. Adopted from [33].*

regulated randomized controlled trials (RCTs). Measuring treatment outcomes of one intervention in patients with complex diseases for whom it would be unethical to drop most ongoing treatments. The numbers to be included in RCTs for demonstrating superiority in effect are too small to identify sometimes rare side effects. The blinding in RCTs cannot be maintained sufficiently long to assess the long-term impact. Building evidence is often a step-wise process, where an effect is noted and reported in a case report. These findings can be confirmed in retrospective and prospective studies, and if possible, the effect can be compared to a placebo or another treatment in an RCT.

The debate regarding these research design issues within conventional medicine has risen in parallel with the growing emphasis on team-based medicine and integrative medical teams for "evidence" of effectiveness and efficacy to meet the standards of "evidence-based medicine."

These standards are predominantly set out for pharmacological treatment, but the EBM model does not evaluate all parts of acupuncture efficacy and strategies in researching complex interventions.

The «whole system» methodology opens the research on Integrative Medicine efficacy with enhanced EBM validation.

Internal and external validity address the usefulness and effectiveness of a treatment. They are complementary and must be addressed separately in different studies. The results must be seen together. The hierarchy of evidence is one of the internal efficacies, not of evidence in general. Other research methodologies must be used and validated.

The results of observational studies help to target treatments and provide information for future research. The mechanisms of action could be elucidated by basic research, and meta-regression could better explain variability in response. Combining the evidence from different sources in a decision-analytical modeling can be used for economic evaluations [47].

#### **4. Conclusions**

Pain management is shifting from a model of highly specialized pain care to multimodal evidence-informed options fitted to a patient's whole experience of pain and therapeutic goals. Ideas changed due to the emerging science about the impact on pain states by the microbiome, mitochondria, fascia, glia and neuroplasticity, and movement disorders. Evidence-informed practice is based on evaluating and disseminating current research, including biological, medical, and behavioral science, secondary to pain for future pain treatments.

Emerging epigenetic data show that NPIs are valid approaches in chronic disease treatments on par with allopathic therapies regarding goals and risks. These approaches have proven superior to some conventional treatments because they tend not to cause such severe side effects.

It might be interesting to look at the quantitative and qualitative changes resulting from single interventions or combining non-pharmacological interventions to further test their efficacy and safety, as well as to improvise on existing therapeutic strategies to prevent or cure disease and disability.

Illustrated by various clinical situations, the objective of management is to seek synergy in the mechanisms of action of treatments to improve quality of life, reduce the need for xenobiotics, and consequently the side effects participating in vicious circles chronicity.

The current imperative is to determine what works best under what conditions.

Multiple medical problems often face limited treatment options, the increased risk of adverse effects, complex drug interactions, and the concurrent use of multiple medications.

From our current perspective, the potential benefit of including nutrition in personalizing pain medicine is formidable and highly promising. The role of personalized nutrition and nutraceuticals, by considering how they might be helpful in managing chronic pain, as well as their physiological features (such as body mass and microbiome) and pathological ones.

The need for a multidisciplinary evaluation and treatment focusing on drug metabolism and chronobiology is highlighted. This multimodal approach influences pain via synergistic non-drug associations like pharmaco-nutritional, acupuncture, neuro-acupuncture, and PEA. Acupuncture in this multidisciplinary model is a multimodal pain regulator. The therapeutic and post-effect are augmented by cellular physiological rehabilitation.

#### **Conflict of interest**

No conflict of interest to declare.

#### **Abbreviations**


*Combining Modern Pharmacology with Integrative Medicine: A Biopsychosocial Model… DOI: http://dx.doi.org/10.5772/intechopen.112906*


#### **Appendix**

The philosophy behind the score sheets states that individuals or groups define a standard for the quality of their performance. Then, they describe the standard in terms of a set of requirements. This set is the score sheet. It allows for peer evaluation and selfevaluation of an activity. Grading proceeds by determining the fraction of requirements fulfilled and is objective and reproducible. The score sheet exists prior to the execution of any activity and thus induces iteration until the performance becomes satisfactory. Any individual or group can adapt the method to any professional activity by selecting the pertinent requirements to fulfill their standard of excellence.

#### **Author details**

Agnes Mazic De Sonis Pain Medicine Pole Neuroscience, Chirec Delta Hospital, Brussels, Belgium

\*Address all correspondence to: a\_mazic@yahoo.com

© 2023 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### **References**

[1] Tick H et al. Evidence-based nonpharmacologic strategies for comprehensive pain care: The consortium pain task force white paper. Explore (New York, N.Y.). 2018;**14**(3):177-211

[2] Hay JL et al. Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. The Journal of Pain. 2009;**10**(3):316-322

[3] Junien C. Early determinants of health and disease: Epigenetics and environment. Bulletin de L'academie Nationale de Medecine. Mar 2011; **195**(3):511-526; discussion 526-527. DOI: 10.1016/s0001-4079(19)32060-6. PMID: 22292301

[4] Kanherkar RR, Bhatia-Dey N, Csoka AB. Epigenetics across the human lifespan. Frontiers in Cell and Development Biology. 2014;**2**:49

[5] Mazic-de Sonis A. Multimodal management of chronic pain: Litterature on the basic research and clinical expertise. In: 14 Congrès National de la SFETD. Lyon, France: La Société Française d'Études et de Traitement de la Douleur; 2014

[6] Plaghki L. Update on nociceptors. In: Quarterly Meeting October. Liège: GRID; 2014

[7] Akbarali HI, Dewey WL. The gutbrain interaction in opioid tolerance. Current Opinion in Pharmacology. 2017;**37**:126-130

[8] Meng J et al. Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-dependent manner. PLoS One. 2013;**8**(1):e54040

[9] Trusheim MR, Berndt ER. Economic challenges and possible policy actions to advance stratified medicine. Personalized Medicine. 2012;**9**(4):413-427

[10] Ozdemir V et al. Mapping translational research in personalized therapeutics: From molecular markers to health policy. Pharmacogenomics. 2007;**8**(2):177-185

[11] Arar N et al. The genome-based knowledge management in cycles model: A complex adaptive systems framework for implementation of genomic applications. Personalized Medicine. 2011;**8**(2):191-205

[12] Sandberg M et al. Different patterns of blood flow response in the trapezius muscle following needle stimulation (acupuncture) between healthy subjects and patients with fibromyalgia and workrelated trapezius myalgia. European Journal of Pain. 2005;**9**(5):497-510

[13] Shinbara H et al. Participation of calcitonin gene related peptide released via axon reflex in the local increase in muscle blood flow following manual acupuncture. Acupuncture in Medicine. 2013;**31**(1):81-87

[14] Carlton SM. Nociceptive primary afferents: They have a mind of their own. The Journal of Physiology. 2014;**592**(16):3403-3411

[15] Pan WX. Bidirectional regulation of acupuncture and its plausible mechanisms. Zhen Ci Yan Jiu. 2019;**44**(11):843-853

[16] Dinan TG et al. Collective unconscious: How gut microbes shape human behavior. Journal of Psychiatric Research. 2015;**63**:1-9

*Combining Modern Pharmacology with Integrative Medicine: A Biopsychosocial Model… DOI: http://dx.doi.org/10.5772/intechopen.112906*

[17] Harris RE et al. Traditional Chinese acupuncture and placebo (sham) acupuncture are differentiated by their effects on mu-opioid receptors (MORs). NeuroImage. 2009;**47**(3):1077-1085

[18] Napadow V et al. Brain correlates of phasic autonomic response to acupuncture stimulation: An eventrelated fMRI study. Human Brain Mapping. 2013;**34**(10):2592-2606

[19] De Gregori M et al. Combining pain therapy with lifestyle: The role of personalized nutrition and nutritional supplements according to the SIMPAR Feed Your Destiny approach. Journal of Pain Research. 2016;**9**:1179-1189

[20] Rea K, Dinan TG, Cryan JF. The microbiome: A key regulator of stress and neuroinflammation. Neurobiol Stress. 2016;**4**:23-33

[21] IASP. Integrative pain medicine: A holistic model of care. IASP: Pain Clinical Update. 2014;**22**:1-6

[22] Ticinesi A et al. Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Scientific Reports. 2017;**7**(1):11102

[23] Burneo JG et al. Weight loss associated with vagus nerve stimulation. Neurology. 2002;**59**(3):463-464

[24] Cork SC et al. Extracellular pH monitoring for use in closed-loop vagus nerve stimulation. Journal of Neural Engineering. 2018;**15**(1):016001

[25] Ikramuddin S et al. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. JAMA. 2014;**312**(9):915-922

[26] Shikora S et al. Vagal blocking improves glycemic control and elevated blood pressure in obese subjects with type 2 diabetes mellitus. Journal of Obesity. 2013;**2013**:245683

[27] Pardo JV et al. Weight loss during chronic, cervical vagus nerve stimulation in depressed patients with obesity: An observation. International Journal of Obesity. 2007;**31**(11):1756-1759

[28] Hu X et al. PLGA-curcumin attenuates opioid-induced hyperalgesia and inhibits spinal CaMKIIα. PLoS One. 2016;**11**(1):e0146393

[29] Teiten MH, Dicato M, Diederich M. Curcumin as a regulator of epigenetic events. Molecular Nutrition & Food Research. 2013;**57**(9):1619-1629

[30] Anand P et al. Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics. 2007;**4**(6):807-818

[31] Nau R et al. Strategies to increase the activity of microglia as efficient protectors of the brain against infections. Frontiers in Cellular Neuroscience. 2014;**8**:138

[32] Hesselink JM, Kopsky DJ. Enhancing acupuncture by low dose naltrexone. Acupuncture in Medicine. 2011;**29**(2):127-130

[33] Toljan K, Vrooman B. Low-dose naltrexone (LDN)-review of therapeutic utilization. Medical Sciences. 2018;**6**(4):82

[34] Zylicz Z, Stork N, Krajnik M. Severe pruritus of cholestasis in disseminated cancer: Developing a rational treatment strategy. A case report. Journal of Pain and Symptom Management. 2005;**29**(1):100-103

[35] Chindalore VL et al. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: A randomized, controlled trial of Oxytrex. The Journal of Pain. 2005;**6**(6):392-399

[36] Webster LR et al. Oxytrex minimizes physical dependence while providing effective analgesia: A randomized controlled trial in low back pain. The Journal of Pain. 2006;**7**(12):937-946

[37] Movafegh A et al. An ultra-low dose of naloxone added to lidocaine or lidocaine-fentanyl mixture prolongs axillary brachial plexus blockade. Anesthesia and Analgesia. 2009;**109**(5):1679-1683

[38] Hay JL et al. Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects. European Journal of Pain. 2011;**15**(3):293-298

[39] Xiao Y et al. A randomized clinical trial of the effects of ultra-low-dose naloxone infusion on postoperative opioid requirements and recovery. Acta Anaesthesiologica Scandinavica. 2015;**59**(9):1194-1203

[40] Firouzian A et al. Ultra-low-dose naloxone as an adjuvant to patient controlled analgesia (PCA) with morphine for postoperative pain relief following lumber discectomy: A doubleblind, randomized, placebo-controlled trial. Journal of Neurosurgical Anesthesiology. 2018;**30**(1):26-31

[41] Gironi M et al. A pilot trial of lowdose naltrexone in primary progressive multiple sclerosis. Multiple Sclerosis. 2008;**14**(8):1076-1083

[42] Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Annals of Neurology. 2010;**68**(2):145-150 [43] Turel AP et al. Low dose naltrexone for treatment of multiple sclerosis: A retrospective chart review of safety and tolerability. Journal of Clinical Psychopharmacology. 2015;**35**(5):609-611

[44] Ludwig MD et al. Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis. Multiple Sclerosis Journal—Experimental, Translational and Clinical. 2016;**2**:2055217316672242

[45] Raknes G, Småbrekke L. Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study. PLoS One. 2017;**12**(11):e0187423

[46] Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;**312**(7040):1215-1218

[47] Philips Z et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technology Assessment. 2004;**8**(36):iii-iv, ix-xi, 1-158

## *Edited by Theodoros Aslanidis and Christos Nouris*

With more than 230 million surgical procedures performed annually worldwide, and 30% or more of people affected by chronic pain globally, pain management is consistently a top priority. Its personal and social burden is enormous and thus much literature and research focuses on pain medicine. Along with the evolution of precision medicine, today's typical pain management strategies include a personalized, multimodal, interdisciplinary treatment approach, which might include pharmacotherapy, psychotherapy, integrative treatments, and invasive procedures. This book presents the latest advancements in pain management, covering a wide field of topics in pain medicine.

*Rosario Pignatello, Pharmaceutical Science Series Editor*

Published in London, UK © 2024 IntechOpen © LucaDAddezio / iStock

Pain Management - From Acute to Chronic and Beyond

IntechOpen Series

Pharmaceutical Science, Volume 1

Pain Management

From Acute to Chronic and Beyond

*Edited by Theodoros Aslanidis and Christos Nouris*